Stem Cell Therapeutics options schizophrenia, MS clinical programs

By Lisa Kerner

Charlotte, N.C., Sept. 13 - Stem Cell Therapeutics Corp. entered into a six-month option to acquire agreement with two researchers from the Max Planck Institute of Experimental Medicine in Germany for up to two additional clinical-stage programs, one in schizophrenia and the other in multiple sclerosis.

The agreement provides Stem Cell Therapeutics with the right, but not the obligation, to acquire one or both of the clinical-stage programs under option. Stem Cell Therapeutics will pay upfront, milestone and clinical trial support costs only if it exercises its options.

Both the schizophrenia and multiple sclerosis programs are based on therapeutic approaches to treating central nervous system disorders with erythropoietin (EPO) and have gone through phase 2 trials.

Stem Cell Therapeutics is a biotechnology company based in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.